Scynexis (SCYX) Enterprise Value (2013 - 2026)
Scynexis (SCYX) posted Enterprise Value of -$36.8 million for Q1 2026, down 72.22% on a QoQ basis from -$21.3 million in Q4 2025, and up 32.24% year-over-year from -$27.8 million in Q1 2025.
Scynexis (SCYX) Enterprise Value (2013 - 2026) Analysis & Trends
Scynexis' Enterprise Value history runs 14 years deep, the most recent figure standing at -$36.8 million for Q1 2026.
- Quarterly Enterprise Value rose 32.24% year-over-year to -$36.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36.8 million (up 32.24% YoY) and the FY2025 annual result came in at -$21.3 million, down 29.44% from the prior year.
- Enterprise Value was -$36.8 million for Q1 2026 at Scynexis, down from -$21.3 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$16.5 million in Q4 2024 and bottomed at -$130.7 million in Q2 2024.
- A 5-year average of -$59.8 million and a median of -$44.8 million in 2025 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2023 — Enterprise Value sank 53.74% — and 2024, when it jumped 72.38%.
- Scynexis' Enterprise Value stood at -$73.5 million in 2022, then soared by 53.16% to -$34.4 million in 2023, then jumped by 52.12% to -$16.5 million in 2024, then retreated by 29.44% to -$21.3 million in 2025, then plunged by 72.22% to -$36.8 million in 2026.
- Business Quant data shows SCYX's Enterprise Value at -$36.8 million in Q1 2026, -$21.3 million in Q4 2025, and -$38.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | -1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -3.74 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -1.94 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -4.05 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -2.15 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -33.59 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -1.80 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -1.32 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -428.00 Mn |
| 10 | Scynexis | 21.55 Mn | -15.20 Mn | - | -36.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.75 Mn |
| Dec 31, 2025 | -21.34 Mn |
| Sep 30, 2025 | -37.98 Mn |
| Jun 30, 2025 | -44.79 Mn |
| Mar 31, 2025 | -54.24 Mn |
| Dec 31, 2024 | -16.49 Mn |
| Sep 30, 2024 | -29.17 Mn |
| Jun 30, 2024 | -130.74 Mn |
| Mar 31, 2024 | -35.86 Mn |
| Dec 31, 2023 | -34.43 Mn |
| Sep 30, 2023 | -105.58 Mn |
| Jun 30, 2023 | -85.54 Mn |
| Mar 31, 2023 | -26.97 Mn |
| Dec 31, 2022 | -73.50 Mn |
| Sep 30, 2022 | -68.68 Mn |
| Jun 30, 2022 | -118.70 Mn |
| Mar 31, 2022 | -95.21 Mn |
| Dec 31, 2021 | -104.48 Mn |
| Sep 30, 2021 | -100.11 Mn |
| Jun 30, 2021 | -112.46 Mn |